ProMetic Life Sciences Inc. (PLI) 2004年年度报告「TSX」.pdf

1、PROMETIC ANNUAL REPORT 2004WERE CREATING A HEALTHIERFUTURE.A DECADE OF INNOVATION AND IMPACTFOUNDED IN 1994,ProMetic Life Sciences Inc.is at the forefront of the biopharmaceutical industry,bringing new technologies and solutions to the challenge of producing high quality,safer,less expensive therape

2、utics.THE COMPANYand its subsidiaries form two divisions,Therapeutic and Enabling Technology.The Therapeutic Division,based in Montreal,has already brought promising compounds into clinical trials and has a number of others with promising results in pre-clinical testing.The Enabling Technology Divis

3、ion,located in Cambridge,England,is responsible for the discovery of the groundbreaking Mimetic LigandTMtechnology that has become the base of so many of ProMetics joint ventures and partnerships,such as those with Serono and GlaxoSmithKline.OUR NEW COMPOUNDSare set to have a huge impact on the bio-

4、pharmaceutical industry,offering new treatment solutions in the field of cancer and autoimmune/inflammatory diseases.OUR ENABLING TECHNOLOGYis already providing building blocksfor new processes that will revolutionize the production of biopharmaceuti-cals and blood filtration.WITH 120 EMPLOYEESat re

5、search and production facilities in Canada and the UK as well as a marketing presence in the U.S.,Europe and Asia,ProMetic is single-mindedly focused on building an organization whose impact will be a healthier future for everyone.006 MESSAGE TO SHAREHOLDERS011 ENABLING TECHNOLOGY012 THERAPEUTIC PIP

6、ELINE014 KEY MILESTONES018 MD&A025 FINANCIAL STATEMENTS028 NOTES048 BOARD OF DIRECTORS049 EXTERNAL SCIENTIFIC ADVISORS050 ADDITIONAL INFORMATIONNet Loss per Share0.000.050.100.150.200.25$0.23$0.17R&D Expenses(in millions of Canadian dollars)03.06.09.012.015.013.514.3Revenue(in millions of Canadian d